Evidence map›Paper›PMID 42846687›Full record

ArticleBlood immunology & cellular therapy2026

B7-H3 expression impacts outcomes in myeloma and is targetable with an NK cell engager.

Aimee M Merino, Bartosz Grzywacz, Hayden Hamsher, Young Vue, Hazel Reilly, Benjamin Miller, Petra Krhovska, Colleen Forster, Zachary Davis, Laura Bendzick and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood immunology & cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Aimee M MerinoBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota; Minneapolis, MN.
Bartosz GrzywaczDepartment of Pathology, Beth Israel Deaconess; Boston, MA.
Hayden HamsherBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota; Minneapolis, MN.
Young VueBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota; Minneapolis, MN.
Hazel ReillyDepartment of Medicine, Karolinska Institute; Stockholm, Sweden.
Benjamin MillerBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota; Minneapolis, MN.
Petra KrhovskaHematology and Oncology, University of Olomouc; Olomouc, Slovakia.
Colleen ForsterBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota; Minneapolis, MN.
Zachary DavisBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota; Minneapolis, MN.
Laura BendzickBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota; Minneapolis, MN.
Megan WeivodaBiochemistry and Molecular Biology, Mayo Clinic; Rochester, MN.
Neha SharmaBiochemistry and Molecular Biology, Mayo Clinic; Rochester, MN.
Anders NarumBiochemistry and Molecular Biology, Mayo Clinic; Rochester, MN.
Ryan ShanleyBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota; Minneapolis, MN.
Martin FelicesBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota; Minneapolis, MN.
Nicholas A ZorkoBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota; Minneapolis, MN.
Evren AliciDepartment of Medicine, Karolinska Institute; Stockholm, Sweden.
Jeffrey S MillerBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota; Minneapolis, MN.

Funding

Understanding and improving responses to adaptive NK cell therapy for leukemia and multiple myelomaK08CA255426 · NCI · UNIVERSITY OF MINNESOTA · PI MERINO, AIMEE · 2021 to 2025
$744k
NCI NIH HHS K08 CA255426NCI NIH HHS L30 CA242713
6 · The paper itself

Abstract

B7-H3 acts as a checkpoint inhibitor, influences the tumor microenvironment, and is necessary for osteoclast (OC) development. Given its dual roles in promoting cancer survival and bone breakdown, we looked at its expression pattern in >200 multiple myeloma (MM) patients and association with cytogenetic abnormalities and outcomes. We found that most newly diagnosed patients had B7-H3

Indexed as

B7-H3bone lesionMDSCmultiple myelomanatural killer engagerosteoclastpathologic fractureTriKE

Identifiers

PMID42846687
PMCPMC13645307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.